000131805 001__ 131805
000131805 005__ 20240229105014.0
000131805 0247_ $$2doi$$a10.1002/ijc.31138
000131805 0247_ $$2pmid$$apmid:29082588
000131805 0247_ $$2ISSN$$a0020-7136
000131805 0247_ $$2ISSN$$a1097-0215
000131805 0247_ $$2altmetric$$aaltmetric:29489770
000131805 037__ $$aDKFZ-2018-00102
000131805 041__ $$aeng
000131805 082__ $$a610
000131805 1001_ $$00000-0002-2095-2426$$aSchmidt, Martina E$$b0$$eFirst author
000131805 245__ $$aDeterminants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up.
000131805 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000131805 3367_ $$2DRIVER$$aarticle
000131805 3367_ $$2DataCite$$aOutput Types/Journal article
000131805 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521447626_11799
000131805 3367_ $$2BibTeX$$aARTICLE
000131805 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131805 3367_ $$00$$2EndNote$$aJournal Article
000131805 520__ $$aFatigue is common in cancer survivors but often insufficiently treated. Due to its complexity a one-size-fits-all treatment seems not appropriate. To gain more information on influencing factors and sub-dimensions of fatigue we investigated potential determinants and correlates of physical, affective, and cognitive fatigue in breast cancer survivors during and after adjuvant therapy. Within the follow-up of two randomized controlled trials physical, affective, and cognitive fatigue were repeatedly assessed during and up to 12 months after cancer therapy with the 20-item Fatigue Assessment Questionnaire in 255 breast cancer survivors. Determinants of the different fatigue dimensions over time were explored with linear mixed models. Chemotherapy appeared as significant precipitating factor for physical fatigue. However, type of cancer therapy had no impact on fatigue one year post-treatment. Obesity was significantly associated with increased physical fatigue throughout all time points (Δ=15.5 at 12 months) whereas exercise appeared to be beneficial (Δ = -6.3). In contrast, affective fatigue was significantly associated with poor social support and worries about the future. In addition, poor sleep quality and previous use of psychopharmaceuticals were significantly associated with physical, affective, as well as cognitive fatigue. Further, hot flashes were associated with increased physical and cognitive fatigue. In conclusion, the broad diagnosis fatigue in cancer survivors needs to be recognized as a diversity of symptoms determined by specific characteristics and likely different etiologies. Taking potential influencing factors such as obesity, physical inactivity, sleep problems, hot flashes, lack of social support, or psychological disorders into consideration might enable a better, individually-tailored fatigue treatment.
000131805 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000131805 588__ $$aDataset connected to CrossRef, PubMed,
000131805 7001_ $$aWiskemann, Joachim$$b1
000131805 7001_ $$aSchneeweiss, Andreas$$b2
000131805 7001_ $$aPotthoff, Karin$$b3
000131805 7001_ $$aUlrich, Cornelia M$$b4
000131805 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b5$$eLast author$$udkfz
000131805 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31138$$gVol. 142, no. 6, p. 1148 - 1157$$n6$$p1148 - 1157$$tInternational journal of cancer$$v142$$x0020-7136$$y2018
000131805 909CO $$ooai:inrepo02.dkfz.de:131805$$pVDB
000131805 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-2095-2426$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131805 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000131805 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000131805 9141_ $$y2018
000131805 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131805 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131805 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131805 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131805 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000131805 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131805 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131805 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131805 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131805 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000131805 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131805 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000131805 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000131805 980__ $$ajournal
000131805 980__ $$aVDB
000131805 980__ $$aI:(DE-He78)G210-20160331
000131805 980__ $$aUNRESTRICTED